GLP-1RA has been placed prominently in the international recommendations for the treatment of T2D as the first injectable agent before insulin due to the advantageous outcomes in cardiovascular safety studies that demonstrated a reduction of the combined cardiovascular endpoint three-component major adverse cardiovascular event (MACE-3
Research into triple-agonist peptides such as Retatrutide has expanded significantly since 2020, with published Phase 2 data (Jastreboff et al., 2023, New England Journal of Medicine) indicating substantial effects in human clinical trials on body weight and glycaemic parameters
The American Diabetes Association (ADA) Standards of Care 2019 recommend diligent monitoring and avoidance of hypoglycemic events in older adults with T2D, stating that hypoglycemia should be assessed and managed by adjusting glycemic targets and pharmacologic interventions, adding that in older adults at increased risk of hypoglycemia, medication classes with low risk of hypoglycemia are preferred [27]
But it does mean that consistent delivery is arguably more important, because inconsistent absorption could affect the balance of receptor activation
Weight loss medication
Retatrutide is taken as a once-weekly injection and follows a step-up dosing approach , meaning its started low and slowly increases over time
